STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more

The U.S. Food and Drug Administration held a public meeting on Monday to establish safety and access standards for psychedelic therapies, as the Trump administration pushes to bring these programs to market. Doctors, veterans, pharmacists, and therapists attended the four-hour hearing to discuss practical issues surrounding the testing and delivery of these therapies, such as provider training, patient screening and monitoring, access, reimbursement, clinic capacity, and long-term safety data collection.

GSK has expanded its pipeline by acquiring global rights to a multiple myeloma treatment from China's Chimagen Biosciences for up to $750 million. This deal focuses on a "potential first-in-class" trispecific T-cell engager that promises to combine good targeting of multiple myeloma cells with improved safety compared to other TCEs for the blood cancer. The candidate, whose identity remains undisclosed, is currently in preclinical-stage development and is set to begin human testing next year.